SG11202009872YA - Stable antibody formulation - Google Patents

Stable antibody formulation

Info

Publication number
SG11202009872YA
SG11202009872YA SG11202009872YA SG11202009872YA SG11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA
Authority
SG
Singapore
Prior art keywords
hhh
eee
koh
hoch
kok
Prior art date
Application number
SG11202009872YA
Other languages
English (en)
Inventor
Murali Jayaraman
Anuja Chandrasekar
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68164052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11202009872Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of SG11202009872YA publication Critical patent/SG11202009872YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202009872YA 2018-04-10 2019-04-10 Stable antibody formulation SG11202009872YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841013645 2018-04-10
PCT/IN2019/050291 WO2019198099A1 (en) 2018-04-10 2019-04-10 Stable antibody formulation

Publications (1)

Publication Number Publication Date
SG11202009872YA true SG11202009872YA (en) 2020-11-27

Family

ID=68164052

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009872YA SG11202009872YA (en) 2018-04-10 2019-04-10 Stable antibody formulation

Country Status (10)

Country Link
US (1) US12024561B2 (enExample)
EP (1) EP3773695A4 (enExample)
JP (1) JP2021521168A (enExample)
CN (1) CN112243379A (enExample)
AU (1) AU2019251452A1 (enExample)
BR (1) BR112020020741A2 (enExample)
CO (1) CO2020013545A2 (enExample)
SG (1) SG11202009872YA (enExample)
WO (1) WO2019198099A1 (enExample)
ZA (1) ZA202006262B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103040732B (zh) * 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
UY34054A (es) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN112292146A (zh) * 2018-04-10 2021-01-29 雷迪博士实验室有限公司 治疗性抗体的稳定的制剂
SG11202009874QA (en) * 2018-04-10 2020-11-27 Dr Reddys Laboratories Ltd Antibody formulation
AR119268A1 (es) * 2019-06-10 2021-12-09 Millennium Pharm Inc Métodos de purificación de anticuerpos y composiciones de estos
CA3143167A1 (en) * 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Methods of producing an anti-.alpha.4.beta.7 antibody

Also Published As

Publication number Publication date
WO2019198099A1 (en) 2019-10-17
EP3773695A1 (en) 2021-02-17
JP2021521168A (ja) 2021-08-26
AU2019251452A2 (en) 2020-12-03
CO2020013545A2 (es) 2021-01-18
EP3773695A4 (en) 2021-12-22
CN112243379A (zh) 2021-01-19
ZA202006262B (en) 2023-01-25
BR112020020741A2 (pt) 2021-01-19
US12024561B2 (en) 2024-07-02
AU2019251452A1 (en) 2020-11-26
US20210253714A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
IL269499A (en) Stable antibody formulation
ZA202006263B (en) Antibody formulation
SG11202103064YA (en) Antibody formulation
IL282617A (en) Aerosol formulation
SG11202104300PA (en) Antibody formulation
IL281255A (en) Csf-1r antibody formulation
SG11202008399QA (en) Antibodies
IL282567A (en) Aerosol formulation
PL3873245T3 (pl) Formulacja ulegająca aerozolowaniu
IL282589A (en) Aerosol formulation
GB201816447D0 (en) Formulation
SG11202102875YA (en) Anti-fgfr2 antibody formulations
GB201801614D0 (en) Formulation
IL282461A (en) Aerosol formulation
SG11202104012QA (en) Antibody formulations
IL282697A (en) Aerosol formulation
GB201817863D0 (en) Aerosolisable formulation
ZA202006262B (en) Stable antibody formulation
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201807312D0 (en) Formulation
HK40061150A (en) Antibody formulation
HK40048229A (en) Antibody formulation
HK40025055A (en) Stable anti-osmr antibody formulation
GB201817866D0 (en) Aerosolisable formulation